'OSL will be scrutinised on their results over the next few years to prove the efficacy of the device". Suzuki- pleased to see a few of us on here who've reasonably pointed out a few holes in things have clealry had some influence on you for you to now acknowledge that the device could be entering the market place with its efficacy indeed completely unproven. Not "down-ramping" but simply stating the bleedin' obvious. But I guess that's why it's a spec stock.
For anybody interested in seeing more about what actual 'state of art' chemo gets you (that is, in the current decade), check out German NEOLAP study, n=168, randomised study. Presented at ESMO, comparing folfirininox and gem-abr in unresectable local advanced panc cancer. Freely available if you google it.
exciting weeks ahead possibly!
OSL Price at posting:
18.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)